Why this matters to you

Living with a grade 2 glioma brings complex uncertainty – risk of seizures, timings of treatment, and whether to have treatment. A new trial is exploring whether a targeted drug called Vorasidenib could give people with low-grade glioma more options, potentially delaying the need for surgery, radiotherapy, or chemotherapy while maintaining quality of life. But here’s what makes this different: we want to hear from you first.

Your experiences, concerns, and priorities matter. Before this trial moves forward, we need insights from the people it’s designed to help.

Who should attend

People diagnosed with grade 2 glioma who want to contribute to research that could benefit their own care and that of future patients.

This session is also open to those who are already taking Vorasidenib.